Research programme: protein folding modulators - Reata Pharmaceuticals

Drug Profile

Research programme: protein folding modulators - Reata Pharmaceuticals

Alternative Names: Protein folding modulators - Reata Pharmaceuticals; Protein misfolding reagents for neurodegenerative diseases - Reata Pharmaceuticals; RTA 801; SOD1 reactivators - Reata Pharmaceuticals; SOD1 stabilisers - Reata Pharmaceuticals

Latest Information Update: 28 Jun 2011

Price : $50

At a glance

  • Originator Reata Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Alpha-synuclein inhibitors; Amyloid beta-protein inhibitors; Protein folding modulators; Superoxide dismutase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Research Alzheimer's disease; Amyotrophic lateral sclerosis; Huntington's disease; Parkinson's disease

Most Recent Events

  • 01 Jun 2011 Early research in Parkinson's disease in USA (PO)
  • 01 Jun 2011 Early research in Huntington's disease in USA (PO)
  • 01 Jun 2011 Early research in Amyotrophic lateral sclerosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top